EC grants orphan drug status for Santen's sirolimus to treat chronic non-infectious uveitis

Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan) today announced the European Commission (EC) has granted orphan drug status for sirolimus (DE-109) for the treatment of chronic non-infectious uveitis. The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) in June. Orphan designation will be published on the EMA website.

Source:

Santen Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Santen Pharmaceutical Co., Ltd.. (2020, February 01). EC grants orphan drug status for Santen's sirolimus to treat chronic non-infectious uveitis. News-Medical. Retrieved on May 25, 2020 from https://www.news-medical.net/news/20110908/EC-grants-orphan-drug-status-for-Santens-sirolimus-to-treat-chronic-non-infectious-uveitis.aspx.

  • MLA

    Santen Pharmaceutical Co., Ltd.. "EC grants orphan drug status for Santen's sirolimus to treat chronic non-infectious uveitis". News-Medical. 25 May 2020. <https://www.news-medical.net/news/20110908/EC-grants-orphan-drug-status-for-Santens-sirolimus-to-treat-chronic-non-infectious-uveitis.aspx>.

  • Chicago

    Santen Pharmaceutical Co., Ltd.. "EC grants orphan drug status for Santen's sirolimus to treat chronic non-infectious uveitis". News-Medical. https://www.news-medical.net/news/20110908/EC-grants-orphan-drug-status-for-Santens-sirolimus-to-treat-chronic-non-infectious-uveitis.aspx. (accessed May 25, 2020).

  • Harvard

    Santen Pharmaceutical Co., Ltd.. 2020. EC grants orphan drug status for Santen's sirolimus to treat chronic non-infectious uveitis. News-Medical, viewed 25 May 2020, https://www.news-medical.net/news/20110908/EC-grants-orphan-drug-status-for-Santens-sirolimus-to-treat-chronic-non-infectious-uveitis.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments